EP3793982A4 - Inhibiteurs à petites molécules de la translocation nucléaire du récepteur des androgènes pour traiter le cancer de la prostate résistant à la castration - Google Patents

Inhibiteurs à petites molécules de la translocation nucléaire du récepteur des androgènes pour traiter le cancer de la prostate résistant à la castration Download PDF

Info

Publication number
EP3793982A4
EP3793982A4 EP19803487.8A EP19803487A EP3793982A4 EP 3793982 A4 EP3793982 A4 EP 3793982A4 EP 19803487 A EP19803487 A EP 19803487A EP 3793982 A4 EP3793982 A4 EP 3793982A4
Authority
EP
European Patent Office
Prior art keywords
castration
treatment
prostate cancer
small molecule
androgen receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP19803487.8A
Other languages
German (de)
English (en)
Other versions
EP3793982A1 (fr
Inventor
John Milligan
Serene TAI
Joel B. Nelson
James K. Johnson
Erin M. Skoda
Zhou Wang
Keita TAKUBO
Peter Wipf
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pittsburgh
Original Assignee
University of Pittsburgh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Pittsburgh filed Critical University of Pittsburgh
Publication of EP3793982A1 publication Critical patent/EP3793982A1/fr
Publication of EP3793982A4 publication Critical patent/EP3793982A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/14—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP19803487.8A 2018-05-14 2019-05-13 Inhibiteurs à petites molécules de la translocation nucléaire du récepteur des androgènes pour traiter le cancer de la prostate résistant à la castration Withdrawn EP3793982A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862671254P 2018-05-14 2018-05-14
PCT/US2019/032033 WO2019222105A1 (fr) 2018-05-14 2019-05-13 Inhibiteurs à petites molécules de la translocation nucléaire du récepteur des androgènes pour traiter le cancer de la prostate résistant à la castration

Publications (2)

Publication Number Publication Date
EP3793982A1 EP3793982A1 (fr) 2021-03-24
EP3793982A4 true EP3793982A4 (fr) 2022-05-11

Family

ID=68541064

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19803487.8A Withdrawn EP3793982A4 (fr) 2018-05-14 2019-05-13 Inhibiteurs à petites molécules de la translocation nucléaire du récepteur des androgènes pour traiter le cancer de la prostate résistant à la castration

Country Status (4)

Country Link
EP (1) EP3793982A4 (fr)
JP (1) JP2021523207A (fr)
CA (1) CA3099739A1 (fr)
WO (1) WO2019222105A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022140464A1 (fr) * 2020-12-22 2022-06-30 Immunomolecular Therapeutics, Inc. Composés et méthodes de traitement de troubles auto-immuns par ciblage de hla-dq2

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017165822A1 (fr) * 2016-03-24 2017-09-28 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Inhibiteur de type petite molécule de la translocation nucléaire du récepteur aux androgènes pour le traitement du cancer de la prostate résistant à la castration

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10980806B2 (en) * 2016-03-24 2021-04-20 University of Pittsburgh—of the Commonwealth System of Higher Education Small molecule inhibitors of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017165822A1 (fr) * 2016-03-24 2017-09-28 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Inhibiteur de type petite molécule de la translocation nucléaire du récepteur aux androgènes pour le traitement du cancer de la prostate résistant à la castration

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
PAOLA CIAPETTI AND BRUNO GIETHLEN ED - CAMILLE GEORGES WERMUTH: "Chapter 15 - Molecular Variations Based on Isosteric Replacements", 1 January 2008, THE PRACTICE OF MEDICINAL CHEMISTRY (THIRD EDITION), ELSEVIER, NL, PAGE(S) 290 - 342, ISBN: 978-0-12-374194-3, XP009142466 *
See also references of WO2019222105A1 *

Also Published As

Publication number Publication date
JP2021523207A (ja) 2021-09-02
CA3099739A1 (fr) 2019-11-21
EP3793982A1 (fr) 2021-03-24
WO2019222105A1 (fr) 2019-11-21

Similar Documents

Publication Publication Date Title
EP3781564C0 (fr) Dérivés de pyridazine pour le traitement du cancer
EP3433239A4 (fr) Inhibiteur de type petite molécule de la translocation nucléaire du récepteur aux androgènes pour le traitement du cancer de la prostate résistant à la castration
EP3494142A4 (fr) Anticorps anti-siglec-7 pour le traitement du cancer
IL273919A (en) Antiandrogens for the treatment of castration-resistant prostate cancer without metastases
EP3891294A4 (fr) Méthodes de traitement du cancer de la prostate résistant à la castration et sensible à la castration
EP3565558A4 (fr) Polythérapie pour le traitement du cancer
EP3380495A4 (fr) Composés peptidiques et conjugués peptidiques destinés au traitement du cancer par chimiothérapie à médiation par un récepteur
IL261047A (en) Taf1 inhibitors for the therapy of cancer
EP3589289A4 (fr) Inhibition de smarca2 pour le traitement du cancer
IL258378A (en) Prostate-specific membrane antigen inhibitors are labeled with 18f and used as imaging agents for prostate cancer.
PT3609497T (pt) Niraparib, acetato de abiraterona e prednisona para o tratamento do cancro da próstata
EP3469101A4 (fr) Procédés et compositions pour le diagnostic et le traitement du cancer de la prostate
EP3796891A4 (fr) Constructions thérapeutiques pour le traitement du cancer
EP3565560A4 (fr) Procédés prédictifs et diagnostiques pour le cancer de la prostate
EP3671214A4 (fr) Procédé de dépistage d'un patient atteint d'un cancer de la prostate basé sur un variant de récepteur d'androgènes
EP3791877A4 (fr) Agent prophylactique ou thérapeutique contre le cancer de la prostate
EP3793544A4 (fr) Compositions bifonctionnelles pour le traitement du cancer
IL281281A (en) Combined treatment for prostate cancer
EP3793982A4 (fr) Inhibiteurs à petites molécules de la translocation nucléaire du récepteur des androgènes pour traiter le cancer de la prostate résistant à la castration
EP3449922A4 (fr) Dérivés de l'indazol pour le traitement du cancer
EP3897602A4 (fr) Associations pharmaceutiques pour le traitement du cancer
IL286353A (en) Iademastat combinations for cancer treatment
EP3781592A4 (fr) Traitement du cancer de la prostate au moyen de récepteurs antigéniques chimériques
EP3781130A4 (fr) Combinaisons thérapeutiques pour le traitement du cancer
EP3630754B8 (fr) Composes d'isoindoline-acetylene pour le traitement du cancer

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20201209

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 35/00 20060101ALI20211220BHEP

Ipc: A61K 31/498 20060101ALI20211220BHEP

Ipc: A61K 31/496 20060101ALI20211220BHEP

Ipc: A61K 31/495 20060101ALI20211220BHEP

Ipc: A61K 31/407 20060101ALI20211220BHEP

Ipc: A61K 31/403 20060101ALI20211220BHEP

Ipc: A61K 31/40 20060101ALI20211220BHEP

Ipc: A61K 31/165 20060101ALI20211220BHEP

Ipc: A61K 31/12 20060101ALI20211220BHEP

Ipc: C07D 487/04 20060101ALI20211220BHEP

Ipc: C07D 233/61 20060101ALI20211220BHEP

Ipc: C07D 207/08 20060101ALI20211220BHEP

Ipc: C07D 207/06 20060101ALI20211220BHEP

Ipc: C07D 409/02 20060101ALI20211220BHEP

Ipc: C07C 49/563 20060101ALI20211220BHEP

Ipc: C07D 209/52 20060101ALI20211220BHEP

Ipc: C07D 295/185 20060101AFI20211220BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20220412

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 35/00 20060101ALI20220406BHEP

Ipc: A61K 31/498 20060101ALI20220406BHEP

Ipc: A61K 31/496 20060101ALI20220406BHEP

Ipc: A61K 31/495 20060101ALI20220406BHEP

Ipc: A61K 31/407 20060101ALI20220406BHEP

Ipc: A61K 31/403 20060101ALI20220406BHEP

Ipc: A61K 31/40 20060101ALI20220406BHEP

Ipc: A61K 31/165 20060101ALI20220406BHEP

Ipc: A61K 31/12 20060101ALI20220406BHEP

Ipc: C07D 487/04 20060101ALI20220406BHEP

Ipc: C07D 233/61 20060101ALI20220406BHEP

Ipc: C07D 207/08 20060101ALI20220406BHEP

Ipc: C07D 207/06 20060101ALI20220406BHEP

Ipc: C07D 409/02 20060101ALI20220406BHEP

Ipc: C07C 49/563 20060101ALI20220406BHEP

Ipc: C07D 209/52 20060101ALI20220406BHEP

Ipc: C07D 295/185 20060101AFI20220406BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20221115